# EDGAR Filing Document

**Accession Number:** 0001661181
**File Stem:** 0002064832-25-000013
**Filing Date:** 2025-11
**Character Count:** 8989
**Document Hash:** faa694c09eac4f2b07b55a888ab74ad0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002064832-25-000013.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0002064832-25-000013

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250514

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** NUSSDORF GLENN H
- **CENTRAL INDEX KEY:** 0001244191

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37906
- **FILM NUMBER:** 251445306

**MAIL ADDRESS:**
- **STREET 1:** C/O ORGANOGENESIS HOLDINGS INC.
- **STREET 2:** 85 DAN ROAD
- **CITY:** CANTON
- **STATE:** MA
- **ZIP:** 02021
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Organogenesis Holdings Inc.
- **CENTRAL INDEX KEY:** 0001661181
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 85 DAN ROAD
- **CITY:** CANTON
- **STATE:** MA
- **ZIP:** 02021
- **BUSINESS PHONE:** 781-575-0775

**MAIL ADDRESS:**
- **STREET 1:** 85 DAN ROAD
- **CITY:** CANTON
- **STATE:** MA
- **ZIP:** 02021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avista Healthcare Public Acquisition Corp.
- **DATE OF NAME CHANGE:** 20151215

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>NUSSDORF GLENN H<br><sub>(Last) (First) (Middle)</sub><br>35 SAWGRASS DRIVE<br><sub>(Street)</sub><br>BELLPORT, NY 11713<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-05-14 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Organogenesis Holdings Inc. [ ORGO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2025-05-14 |  | P |  | 251001 | A | 3.0878<sup>(1)</sup> | 251001 | I | By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 |
| Class A Common Stock | 2025-05-15 |  | P |  | 107494 | A | 2.9862<sup>(2)</sup> | 358495 | I | By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 |
| Class A Common Stock | 2025-06-09 |  | S<sup>(5)</sup> |  | 4156 | D | 3.5003<sup>(3)</sup> | 354339 | I | By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 |
| Class A Common Stock | 2025-06-10 |  | S<sup>(5)</sup> |  | 18620 | D | 3.5583<sup>(4)</sup> | 335719 | I | By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 |
| Class A Common Stock |  |  |  |  |  |  |  | 3065591 | D |  |
| Class A Common Stock |  |  |  |  |  |  |  | 918680 | I | By GN 2016 Family Trust u/a/d August 12, 2016 |
| Class A Common Stock |  |  |  |  |  |  |  | 7928570 | I | By GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.10, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

(2) The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.9725 to $3.00, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

(3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.505, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

(4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.59, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

(5) The reporting person's sale of an aggregate of 22,776 shares of the issuer's Class A common stock on June 9, 2025 and June 10, 2025 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, with the reporting person's purchase of 22,776 shares of the issuer's Class A common stock on May 15, 2025. The reporting person has paid to the issuer an amount equal to $13,285.24, representing the full amount of the profit realized in connection with the short-swing transaction ($12,971.78) plus interest at the rate of 6% per annum through the date of payment ($313.46).

**Signature:** /s/ William R. Kolb, Attorney-in-Fact  
**Date:** 2025-11-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**